The SLea/x-enriched MM population displays an aggressive phenotype characterized by a complete resistance to bortezomib in vivo, which can be reverted by blocking E-selectin with small glycomimetic molecules or by inhibiting sialyltransferases [21,22]. This evidence concerns the gene SELE and Miyoshi myopathy.